Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin

Clinical Cancer Research

Volumn 17, Issue 8, 2011, Pages 2581-2590

  Zucali, Paolo Andrea ^a   Giovannetti, Elisa ^c   Destro, Annarita ^a   Mencoboni, Manlio ^b   Ceresoli, Giovanni Luca ^a   Gianoncelli, Letizia ^a   Lorenzi, Elena ^a   De Vincenzo, Fabio ^a   Simonelli, Matteo ^a   Perrino, Matteo ^a   Bruzzone, Andrea ^b   Thunnissen, Erik ^c   Tunesi, Gianni ^b   Giordano, Laura ^a   Roncalli, Massimo ^a   Peters, Godefridus J ^a   Santoro, Armando ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b VILLA SCASSI HOSPITAL   (Italy)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MESSENGER RNA; PEMETREXED; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; FEMALE; GENETIC POLYMORPHISM; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RISK ASSESSMENT; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FREQUENCY; GENOTYPE; GLUTAMATES; GUANINE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MESOTHELIOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLEURAL NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME;

EID: 79954607787     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2873     Document Type: Article

References (48)

1. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer 1999;79:666-72. (Pubitemid 29046253)
2. Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol 2009;27:2081-90.
3. Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G, et al. Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998;16:145-52. (Pubitemid 28041592)
4. Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the cancer and leukemia group B. Chest 1998;113:723-31. (Pubitemid 28130949)
5. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44. (Pubitemid 46606305)
6. Scagliotti GV, Shin DM, Kindler HL, Vasconcelles MJ, Keppler U, Manegold C, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003;21:1556-61. (Pubitemid 46594110)
7. Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006;24:1443-8. (Pubitemid 46622011)
8. Ceresoli GL, Castagneto B, Zucali PA, Favaretto A, Mencoboni M, Grossi F, et al. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. Br J Cancer 2008;99:51-6. (Pubitemid 351920240)
9. Sancar A. DNA repair in humans. Annu Rev Genet 1995;29:69-105. (Pubitemid 26005337)
10. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andrè F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatinbased adjuvant chemotherapy. N Engl J Med 2006;355:983-91. (Pubitemid 44343542)
11. Darcy K, Tian C, Reed E. A gynecologic oncology group study of platinum-DNA adducts and excision repair cross complementation group 1 expression in optimal, stage III ovarian cancer treated with platinum-taxane chemotherapy. Cancer Res 2007;67:4474-81. (Pubitemid 46815098)
12. Smith S, Su D, Rigault de la Longrais IA, Schwartz P, Puopolo M, Rutherford TJ, et al. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J Clin Oncol 2007;25:5172-9. (Pubitemid 350232247)
13. Kwon HC, Roh MS, Oh SY, Kim SH, Kim MC, Kim JS, et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-flourouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 2007;18:504-9. (Pubitemid 46359630)
14. Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 2007;25:1247-54. (Pubitemid 46640571)
15. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G, et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007;356:800-8. (Pubitemid 46294612)
16. Righi L, Papotti MG, Ceppi P, Billè A, Bacillo E, Molinaro L, et al. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol 2010;28:1534-9.
17. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, et al. LY231514, a pyrrolo [2, 3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997;57:1116-23. (Pubitemid 27138611)
18. Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 2007;6:404-17. (Pubitemid 46332443)
19. Hanauske AR, Eismann U, Oberschmidt O, Pospisil H, Hoffmann S, Hanauske-Abel H, et al. In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression. Invest New Drugs 2007;25:417-23. (Pubitemid 47222911)
20. Giovannetti E, Lemos C, Tekle C, Smid K, Nannizzi S, Rodriguez JA, et al. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol 2008;73:1290-1300. (Pubitemid 351439211)
21. Sigmond J, Backus HH, Wouters D, Temmink OH, Jansen G, Peters GJ, et al. Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 2003;66:431-8. (Pubitemid 36937028)
22. Ceppi P, Volante M, Ferrero A, Righi L, Rapa I, Rosas R, et al. Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res 2008;14:1059-64. (Pubitemid 351302551)
23. Bepler G, Sommers KE, Cantor A, Li X, Sharma A, Williams C, et al. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol 2008;3:1112-8.
24. Shintani Y, Ohta M, Hirabayashi H, Tanaka H, Iuchi K, Nakagawa K, et al. New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction. Int J Cancer 2003;104:790-95. (Pubitemid 36418519)
25. Hashimoto H, Ozeki Y, Sato M, Obara K, Matsutani N, Nakagishi Y, et al. Significance of thymidylate synthase gene expression level in patients with adenocarcinoma of the lung. Cancer 2006;106:1595-1601.
26. Zheng Z, Li X, Schell MJ, Chen T, Boulware D, Robinson L, et al. Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer. Cancer 2008;112:2765-73. (Pubitemid 351969222)
27. Kim JH, Lee KW, Jung Y, Kim TY, Ham HS, Jong HS, et al. Cytotoxic effects of pemetrexed in gastric cancer cells. Cancer Sci 2005;96:365-71. (Pubitemid 41007472)
28. Ryu JS, Hong YC, Han HS, Lee JE, Kim S, Park YM, et al. Association between polymorphisms of ERCC1 and XPD and survival in nonsmallcell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 2004;44:311-16. (Pubitemid 38609439)
29. Iacopetta B, Grieu F, Joseph D, Elsaleh H. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 2001;85:827-30. (Pubitemid 33010548)
30. Villafranca E, Okruzhnov Y, Dominguez MA, García-Foncillas J, Azinovic I, Martínez E, et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 2001;19:1779-86. (Pubitemid 32230880)
31. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei D, Groshen S, Lenz HJ, et al. Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. Int J Colorectal Dis 2002;17:46-9. (Pubitemid 41398991)
32. Wei SZ, Zhan P, Shi MQ, Shi Y, Qian Q, Yu LK, et al. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med Oncol Epub ahead of print 2010 Feb. 9.
33. Mauritz R, Peters GJ. Pharmacogenetics of colon cancer and potential implications for 5 fluorouracil-based chemotherapy. Curr Pharmacogenomics 2006;4:57-67.
34. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma: from the International Mesothelioma Interest Group. Chest 1995;108:1122-8.
35. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004;15:257-60. (Pubitemid 38262625)
36. Jun HJ, Ahn MJ, Kim HS, Yi SY, Han J, Lee SK, et al. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer 2008;99:167-72. (Pubitemid 351920246)
37. Zucali PA, Gallegos Ruiz M, Giovannetti E, Destro A, Varella-Garcia M, Floor K, et al. Role of cMET expression in non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Ann Oncol 2008;19:1605-12.
38. Giovannetti E, Backus HHJ, Wouters D, Ferreira CG, van Houten VM, Brakenhoff RH, et al. Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels. Br J Cancer 2007;96:769-75. (Pubitemid 46376640)
39. Mauritz R, Giovannetti E, Beumer IJ, Smid K, Van Groeningen CJ, Pinedo HM, et al. Polymorphisms in the enhancer region of the thymidylate synthase gene are associated with thymidylate synthase levels in normal tissues but not in malignant tissues of colorectal cancer patients. Clin Colorectal Cancer 2009;8:146-54.
40. Goldstein DB, Tate SK, Sisodiya SM. Pharmacogenetics goes genomic. Nat Rev Genet 2003;4:937-47. (Pubitemid 37474641)
41. Lesko LJ. Personalized medicine: elusive dream or imminent reality? Clin Pharmacol Ther 2007;81:807-16. (Pubitemid 46788303)
42. Røe OD, Anderssen E, Sandeck H, Christensen T, Larsson E, Lundgren S. Malignant pleural mesothelioma: genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets. Lung Cancer 2010;67:57-68. doi:10.1016/j.lungcan. 2009. 03.016.
43. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007;33:9-23. (Pubitemid 46137553)
44. Berghmans T, Paesmans M, Lalami Y, Louviaux I, Luce S, Mascaux C, et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 2002;38:111-21. (Pubitemid 35157753)
45. Akbari M, Otterlei M, Peña-Diaz J, Aas PA, Kavli B, Liabakk NB, et al. Repair of U/G and U/A in DNA by UNG2-associated repair complexes takes place predominantly by short-patch repair both in proliferating and growth-arrested cells. Nucleic Acids Res 2004;32:5486-98. (Pubitemid 39545666)
46. Danesi R, Pasqualetti G, Giovannetti E, Crea F, Altavilla G, Del Tacca M, et al. Pharmacogenomics in non-small-cell lung cancer chemotherapy. Adv Drug Deliv Rev 2009;61:408-17.
47. Ivanov SV, Miller J, Lucito R, Tang C, Ivanova AV, Pei J, et al. Genomic events associated with progression of pleural malignant mesothelioma. Int J Cancer 2009;124:589-99.
48. Chu E, Koeller DM, Casey JL, Drake JC, Chabner BA, Elwood PC, et al. Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. Proc Natl Acad Sci U S A 1991;88:8977-81. (Pubitemid 21915553)